Barry Freedman, MD
Nephrology · Winston Salem, NCNPI 1245215672
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $60,442 of the $66,939 with a category attached, or 90.3%. Astrazeneca UK Limited accounts for 65.9% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $23,704 and has fallen 77.3% since, to $5,390 in 2025. Among nephrology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $2028.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$44K
- Astrazeneca AB$18K
- Renalytix AI, Inc.$4K
- Instrumentation Laboratory Company$1K
- Bard Peripheral Vascular, Inc.$73
Across 13 payments — averaging $266,470 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Renalytix AI, Inc.$2.6M
- Astrazeneca AB$517K
- Astrazeneca UK Limited$373K
What the payments were for
- Consulting fees$60,44290%
- Speaking & faculty fees$4,0006%
- Travel & lodging$1,9403%
- Food & beverage$5581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 7 | $44,087 |
| Astrazeneca AB | 23 | $17,579 |
| Renalytix AI, Inc. | 1 | $4,000 |
| Instrumentation Laboratory Company | 1 | $1,200 |
| Bard Peripheral Vascular, Inc. | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$66,939 in reported general payments places this provider in the 95th percentile of 366 nephrology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClinisolParenteral Amino Acid 15% No.5 | 52 | $9,300 |
| ProsolParenteral Amino Acid 20% No.1 | 21 | $2,260 |
| Sevelamer Carbonate | 20 | $1,357 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Winston Salem
- Michael RoccoWinston Salem$21K
- Anthony BleyerWinston Salem$20K
- Taewoo LeeWinston Salem$14K
- Nicholas McLeanWinston Salem$14K
- Andrew SpanglerWinston Salem$9K
- Christopher MarshallWinston Salem$9K
- Scott SatkoWinston Salem$9K
- Alexander HadleyWinston Salem$9K
- Jim EllisonWinston Salem$8K
- Gregory GreenwoodWinston-Salem$947K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.